It is a surprise there is still no announcement by ACR management re the excellent sales of Axiron as reported by Eli Lilly. If they ever wanted to help shareholders and diminish the effect of the constant shorting of ACR stock over the past month now is the time.
I couldn't imagine the previous MD Richard Treagus missing this opportunity, which reminds me have they filled this position yet? I for one want Richard back and quickly.
